-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Deep Track Capital LP Invests $34.44 Million in Agenus Inc. (NASDAQ:AGEN)
Deep Track Capital LP Invests $34.44 Million in Agenus Inc. (NASDAQ:AGEN)
Deep Track Capital LP acquired a new position in shares of Agenus Inc. (NASDAQ:AGEN – Get Rating) in the 1st quarter, according to its most recent disclosure with the SEC. The fund acquired 13,998,491 shares of the biotechnology company's stock, valued at approximately $34,436,000. Agenus comprises approximately 2.2% of Deep Track Capital LP's investment portfolio, making the stock its 17th largest position. Deep Track Capital LP owned about 5.18% of Agenus at the end of the most recent reporting period.
Several other institutional investors have also modified their holdings of the company. U.S. Capital Wealth Advisors LLC acquired a new stake in Agenus during the 1st quarter worth $25,000. Bank of Nova Scotia purchased a new stake in shares of Agenus in the first quarter valued at about $31,000. Covestor Ltd purchased a new stake in shares of Agenus in the fourth quarter valued at about $32,000. Acadian Asset Management LLC purchased a new stake in shares of Agenus in the fourth quarter valued at about $32,000. Finally, Qube Research & Technologies Ltd purchased a new stake in shares of Agenus in the fourth quarter valued at about $40,000. 51.89% of the stock is owned by hedge funds and other institutional investors.
Get Agenus alerts:Wall Street Analysts Forecast Growth
Separately, TheStreet downgraded shares of Agenus from a "c-" rating to a "d" rating in a report on Friday, May 27th.
Agenus Stock Performance
Shares of AGEN stock opened at $2.69 on Friday. Agenus Inc. has a one year low of $1.25 and a one year high of $6.64. The company has a 50 day moving average price of $2.70 and a 200 day moving average price of $2.32. The firm has a market capitalization of $761.70 million, a price-to-earnings ratio of 26.90 and a beta of 1.17.Agenus (NASDAQ:AGEN – Get Rating) last posted its quarterly earnings data on Tuesday, August 9th. The biotechnology company reported ($0.17) EPS for the quarter, beating analysts' consensus estimates of ($0.23) by $0.06. Agenus had a net margin of 3.07% and a return on equity of 11.65%. During the same quarter in the prior year, the business posted ($0.37) EPS. As a group, equities analysts forecast that Agenus Inc. will post -0.7 EPS for the current fiscal year.
About Agenus
(Get Rating)
Agenus Inc, a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Further Reading
- Get a free copy of the StockNews.com research report on Agenus (AGEN)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
Want to see what other hedge funds are holding AGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agenus Inc. (NASDAQ:AGEN – Get Rating).
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.
Deep Track Capital LP acquired a new position in shares of Agenus Inc. (NASDAQ:AGEN – Get Rating) in the 1st quarter, according to its most recent disclosure with the SEC. The fund acquired 13,998,491 shares of the biotechnology company's stock, valued at approximately $34,436,000. Agenus comprises approximately 2.2% of Deep Track Capital LP's investment portfolio, making the stock its 17th largest position. Deep Track Capital LP owned about 5.18% of Agenus at the end of the most recent reporting period.
根據深軌資本有限公司與美國證券交易委員會的最新披露,該公司在第一季度收購了Agenus Inc.(美國證券交易委員會代碼:AGEN-GET評級)的新股票頭寸。該基金收購了這家生物技術公司13,998,491股股票,價值約34,436,000美元。Agenus約佔Deep Track Capital LP投資組合的2.2%,使其成為其第17大頭寸。截至最近一次報告期末,Deep Track Capital LP擁有Agenus約5.18%的股份。
Several other institutional investors have also modified their holdings of the company. U.S. Capital Wealth Advisors LLC acquired a new stake in Agenus during the 1st quarter worth $25,000. Bank of Nova Scotia purchased a new stake in shares of Agenus in the first quarter valued at about $31,000. Covestor Ltd purchased a new stake in shares of Agenus in the fourth quarter valued at about $32,000. Acadian Asset Management LLC purchased a new stake in shares of Agenus in the fourth quarter valued at about $32,000. Finally, Qube Research & Technologies Ltd purchased a new stake in shares of Agenus in the fourth quarter valued at about $40,000. 51.89% of the stock is owned by hedge funds and other institutional investors.
其他幾家機構投資者也調整了對該公司的持股。美國資本財富顧問公司(U.S.Capital Wealth Advisors LLC)在第一季度收購了Agenus價值2.5萬美元的新股份。豐業銀行在第一季度購買了價值約3.1萬美元的Agenus新股。Covestor Ltd在第四季度購買了Agenus的新股份,價值約3.2萬美元。Acadian Asset Management LLC在第四季度購買了Agenus的新股份,價值約3.2萬美元。最後,Qube Research&Technologies Ltd在第四季度購買了Agenus的新股份,價值約為4萬美元。51.89%的股票由對衝基金和其他機構投資者持有。
Wall Street Analysts Forecast Growth
華爾街分析師預測經濟增長
Separately, TheStreet downgraded shares of Agenus from a "c-" rating to a "d" rating in a report on Friday, May 27th.
另外,華爾街在5月27日星期五的一份報告中將Agenus的股票評級從C-下調至D。
Agenus Stock Performance
Agenus股票表現
Agenus (NASDAQ:AGEN – Get Rating) last posted its quarterly earnings data on Tuesday, August 9th. The biotechnology company reported ($0.17) EPS for the quarter, beating analysts' consensus estimates of ($0.23) by $0.06. Agenus had a net margin of 3.07% and a return on equity of 11.65%. During the same quarter in the prior year, the business posted ($0.37) EPS. As a group, equities analysts forecast that Agenus Inc. will post -0.7 EPS for the current fiscal year.
納斯達克(Agen-Get Rating)最近一次公佈季度收益數據是在8月9日,星期二。這家生物技術公司公佈了該季度每股收益(0.17美元),比分析師普遍預期的(0.23美元)高出0.06美元。Agenus的淨利潤率為3.07%,股本回報率為11.65%。在前一年的同一季度,該業務公佈了每股收益(0.37美元)。作為一個整體,股票分析師預計Agenus Inc.本財年每股收益將為0.7%。
About Agenus
關於Agenus
(Get Rating)
(獲取評級)
Agenus Inc, a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Agenus公司是一家臨牀階段的免疫腫瘤學公司,在美國和國際上發現和開發免疫腫瘤學產品。該公司提供Retrocell Display,這是一個抗體表達平臺,用於識別完全人類和人源化的單抗;以及展示技術。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on Agenus (AGEN)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
- 免費獲取StockNews.com關於阿吉恩(Agen)的研究報告
- MarketBeat:回顧一週9/5-9/9
- 為網絡安全股創紀錄的季度做準備
- 汽車市場正在緩慢復甦,這些股票可能表現優異
- DocuSign是否即將發生重大逆轉?
- 石油和天然氣股票:投資可再生能源的安全途徑
Want to see what other hedge funds are holding AGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agenus Inc. (NASDAQ:AGEN – Get Rating).
想看看其他對衝基金持有Agen的是什麼嗎?請訪問HoldingsChannel.com獲取Agenus Inc.(納斯達克代碼:AGEN-GET Rating)的最新13F備案和內幕交易信息。
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Agenus Daily》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Agenus和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧